Developer docs
API playgroundTry for free, no card

Search company profiles

Next&Bio

Full company profile

uuid00039c1

Namestring
Next&Bio
Legal namestring
Next&Bio Inc.
Websiteurl
nextandbio.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organoid drug screening, precision medicine platform, patient-derived organoids, organ-on-a-chip technology, anticancer drug evaluation
Industry1 code
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories62151
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
  • Surgical & Medical Instruments & Apparatus3841
Product category
Organoid-based Drug Screening & Precision Medicine
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Organoid Library Sales & Distribution
TypeOne Time License
Description

Sale of patient-derived organoids (PDOs) to researchers and pharmaceutical companies for disease modeling and drug development. NEXT&BIO offers organoids from lung, colon, breast, and other cancer types with integrated genomic profiles. Organoid bank services for hospitals and research institutions.

nextandbio.com
2Drug Efficacy Evaluation Services (POINT™ Platform)
TypeProfessional Services
Description

Patient-specific anticancer drug sensitivity testing using patient-derived organoids. Services provided to pharmaceutical companies for drug candidate validation and to hospitals for clinical decision support. Revenue from contract research and testing fees.

nextandbio.com
3Brain Organoid and CNS Disease Modeling Services
TypeProfessional Services
Description

HTS-scale brain organoid screening services for neurodegenerative disease drug development. Revenue from research service contracts with biotech and pharmaceutical companies (e.g., Sovargen for brain disease drug efficacy evaluation).

nextandbio.com
4iMag™ Nucleic Acid Extraction Kit Sales
TypeLicensing Royalties
Description

Sales of iMag™ nucleic acid extraction reagent kits for organoid quality verification. Sales and distribution rights licensed to Woongbee Meditech (웅비메디텍). Eight product types covering cell, blood, and tissue samples.

nextandbio.com
5Technology Licensing (HUB Organoids)
TypeLicensing Royalties
Description

Inbound technology licensing from HUB (Netherlands) for all organ types combined with outbound sublicensing and technology sharing capabilities.

nextandbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1POINT™
Description

오가노이드 기반 약물 유효성 평가 플랫폼 - Patient-derived Organoid for Individualized Therapeutics

nextandbio.com
+2 more records
Core offering1 text field

Next&Bio builds and operates an organoid-based precision medicine platform that produces standardized patient-derived organoids (PDOs) and provides drug efficacy evaluation services. Its core offerings include the POINT™ drug sensitivity testing platform, an integrated organoid library with genomic profiles, the Miniature Brain Array for high-throughput CNS drug screening, and MPS (Microphysiological System) organ-on-a-chip technology. The company sells organoids, reagents, and AI image-analysis software to pharmaceutical companies, hospitals, and academic research institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Organoid imaging analysis time reduced by 6x using VONet AI (from ~60 images to 11 images)
+2 more records
Product overview1 text field

Next&Bio is an organoid-based precision medicine platform company offering standardized organoid production and drug evaluation services. The core portfolio consists of the POINT™ drug efficacy evaluation platform, an Organoid Library and Bank System with integrated genomic data, and the Miniature Brain Array™ for HTS-scale brain disease drug screening. The technology suite includes MPS (Microphysiological System) organ-on-a-chip technology and iMag™ nucleic acid extraction kits for quality control. VONet AI software enables 3D organoid structure prediction. The company targets pharmaceutical companies for drug development services and hospitals for clinical precision medicine applications.

Product and service7 records
1POINT™ Drug Efficacy Evaluation Platform
CategoryDrug Efficacy Evaluation Services
Description

Organoid-based drug efficacy evaluation platform that tests anticancer drug sensitivity on patient-derived organoids. Uses standardized 3D culture techniques and high-throughput analysis to select optimal drugs for individual patients. For pharmaceutical companies, hospitals, and oncologists.

2Organoid Library
CategoryBiological Reagents / Cell Lines
Description

Patient-derived organoid library integrating genomic profile information. Contains lung, colon, breast, and other cancer organoids with genetic mutation data for research and drug screening applications. The first organoid library in Korea. For researchers and pharmaceutical companies.

3Organoid Bank System
CategoryBiobanking Services
Description

Organoid banking infrastructure with global-standard SOPs for quality assurance, integrated server for data analysis, and security. Near 400 organoid lines from various organs derived from different patients. For hospitals and research institutions.

4Miniature Brain Array™
CategoryDrug Screening Platform
Description

High-throughput screening platform using 384 or 768 miniature brains arrayed in 96-well plates. Each plate contains uniform miniature brains suitable for bioimaging analysis and drug screening. For biotech and pharmaceutical companies developing CNS disease drugs.

5MPS (Microphysiological System) / Organ-on-a-Chip
CategoryMicrophysiological Systems
Description

Organ-on-a-chip technology implementing human tissue environment using tissue chips, combining microfluidic chip technology with tissue engineering. Solves organoid inhomogeneity through ultra-precise design. For drug development and cell therapy preclinical evaluation.

6iMag™ Nucleic Acid Extraction Reagent Kit
CategoryLaboratory Reagents
Description

Magnetic nano bead-based nucleic acid extraction reagent kit for organoid quality verification. 8 product types (tube, bottle, plate formats) for cell, blood, and tissue samples. Class 1 medical device approved by MFDS. Sales rights licensed to Woongbee Meditech.

7VONet AI Software
CategoryAI Image Analysis Software
Description

Deep learning AI software for organoid 3D structure prediction and analysis. Analyzes minimal confocal microscopy images (minimum 11 vs. 60+ traditional) to predict and render 3D organoid architecture, reducing imaging time by 6x.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Cancer Science Institute of Singapore (CSI) / National University of Singapore (NUS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-30
Description

Joint organoid research center establishment agreement. Plans to build world's largest Asian patient-derived organoid library from Chinese, Indian, Malay, and other Asian cancer patients in Singapore. Joint preclinical evaluation platform development. Prof. Ashok Venkitaraman (NUS Distinguished Professor) leads research. Next&Bio to deploy organoid research personnel to Singapore.

nextandbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-11
Description

Joint development of cell therapy preclinical evaluation platform using patient-derived organoids and MPS (Microphysiological System) for CAR-NK cell therapy efficacy testing against intractable solid tumors. Part of Ministry of Health and Welfare national project 'Advanced Biopharmaceutical Nonclinical Efficacy Evaluation Technology Development based on Microphysiological System.'

3Amplia Therapeutics Limited (호주)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

Joint research contract for pancreatic cancer drug development. Next&Bio creates organoids from KRAS-mutated pancreatic cancer patient tissue and evaluates Amplia's drug candidate narmafotinib (AMP945, FAK inhibitor). First collaboration with a global pharmaceutical company leveraging Next&Bio's organoid technology.

nextandbio.com
4CytoZen (싸이토젠)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-05
Description

Business agreement for CTC (Circulating Tumor Cell)-based organoid production. CytoZen separates intact live CTCs from blood using proprietary technology; Next&Bio cultures them into organoids for anticancer drug sensitivity testing and metastasis research.

nextandbio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-02-28
Description

Research service contract for brain organoid-based drug efficacy evaluation of Sovargen's intractable brain disease treatments (epilepsy, glioblastoma, Alzheimer's). Next&Bio uses iPSC-derived brain organoids for evaluation.

6KTR (한국화학융합시험연구원)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-13
Description

Three-way MOU with Kolmar Korea and KTR for advanced alternative test service platform development. Development of OECD TG-compliant alternative testing service platform using 3D in vitro culture technology for cosmetics and pharmaceutical safety assessment.

nextandbio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-19
Description

Joint research for new drug development using lung and colorectal cancer patient-derived organoids to evaluate anticancer drug candidate LB217 efficacy. L-Base plans to file IND application with UK MHRA based on results.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-04-23
Description

MOU for co-establishment of organoid bank. Plans to systematically store organoids from various cancer types and organs for precision medicine and regenerative medicine research. Joint research with cardiologist Prof. Ahn Young-geun on organoid-based regenerative therapy.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-04-23
Description

Joint research agreement for organoid-based precision medicine and personalized drug screening. Collaboration on cancer organoid research, process development for precision medicine, and co-development of personalized cancer treatment.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-04-23
Description

MOU for co-establishment of organoid bank. Focus on liver, stomach, colorectal, and pancreatic cancer organoids for personalized precision medicine services.

11KIST Europe (한국과학기술연구원 유럽연구소)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-11
Description

Joint research agreement for OECD AOP (Adverse Outcome Pathway) guideline registration using organoid-based animal replacement test methods. Established protocols for liver and lung disease AOP models; registered as OECD development project in June 2022.

nextandbio.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-01
Description

Technology licensing agreement — secured usage rights for all organ types (colon, pancreas, kidney, liver, stomach, lung, ovary) from HUB, the company that pioneered organoid technology under Hans Clevers. Includes technology sharing provisions.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2021-01-01
Description

Co-marketing agreement for drug screening services. Collaborative marketing to pharmaceutical companies and research institutions for organoid-based drug screening offerings.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer of patient-derived organoid technology (founded by Hans Clevers). Next&Bio holds an inbound technology licensing agreement with HUB covering all organ types — they share the same core platform and target pharma R&D customers, making HUB both a licensor and the most direct functional peer.

TypeDirect peer
Description

Global preclinical CRO with extensive patient-derived xenograft (PDX) and increasingly organoid-based oncology services. Comparable to Next&Bio in serving pharma drug-efficacy evaluation, but at materially larger scale with global infrastructure.

TypeDirect peer
Description

Dutch organ-on-a-chip / MPS company offering microfluidic 3D tissue models for drug screening. Direct technology overlap with Next&Bio's MPS offering and shared target market of pharma preclinical development.

4CN Bio
TypeDirect peer
Description

UK-based organ-on-chip / MPS company with single- and multi-organ microphysiological systems used by pharma for ADME/toxicology studies. Comparable to Next&Bio's MPS platform and drug-evaluation service offering.

TypeDirect peer
Description

US organ-on-chip platform company using microfluidic chips to model human organ physiology for pharma and cosmetics safety testing. Comparable in MPS technology and animal-replacement positioning, including OECD-relevant submissions.

TypeDirect peer
Description

Swiss 3D cell-culture and organoid company providing in vitro disease models and toxicology services for pharma. Shares Next&Bio's HTS drug-screening business model and target customer base.

TypeEmerging player
Description

Seattle-based company combining iPSC-derived cells, organoids, and MPS platforms for drug discovery and safety assessment. Partial overlap with Next&Bio's brain organoid and MPS offering, though at earlier commercialization stage.

TypeEmerging player
Description

UK iPSC-derived organoid company providing liver, pancreatic, and intestinal disease models. Comparable in iPSC-derived organoid technology with Next&Bio's standardized organoid production approach.

TypeEmerging player
Description

UK-based organoid and iPSC-derived tissue model company with focus on kidney, liver, retina, and lung models for pharma. Adjacent technology overlap with Next&Bio's organoid portfolio.

TypeEmerging player
Description

US-based company using 3D-printed lymph node organoids and human tissue models for antibody discovery and therapeutic development. Technology-adjacent to Next&Bio's organoid focus, particularly in producing standardized 3D biological structures.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Next&Bio

Organoid-based Drug Screening & Precision Medicinenextandbio.com

Next&Bio firmographics

Firmographics
Name
Next&Bio
Legal name
Next&Bio Inc.
Website
https://nextandbio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Next&Bio industry classification

Industry
Product category
Organoid-based Drug Screening & Precision Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Organoid drug screening
  • Precision medicine platform
  • Patient-derived organoids
  • Organ-on-a-chip technology
  • Anticancer drug evaluation

Where Next&Bio is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Next&Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Organoid Library Sales & Distribution: Sale of patient-derived organoids (PDOs) to researchers and pharmaceutical companies for disease modeling and drug development. NEXT&BIO offers organoids from lung, colon, breast, and other cancer types with integrated genomic profiles. Organoid bank services for hospitals and research institutions.
  2. Drug Efficacy Evaluation Services (POINT™ Platform): Patient-specific anticancer drug sensitivity testing using patient-derived organoids. Services provided to pharmaceutical companies for drug candidate validation and to hospitals for clinical decision support. Revenue from contract research and testing fees.
  3. Brain Organoid and CNS Disease Modeling Services: HTS-scale brain organoid screening services for neurodegenerative disease drug development. Revenue from research service contracts with biotech and pharmaceutical companies (e.g., Sovargen for brain disease drug efficacy evaluation).
  4. iMag™ Nucleic Acid Extraction Kit Sales: Sales of iMag™ nucleic acid extraction reagent kits for organoid quality verification. Sales and distribution rights licensed to Woongbee Meditech (웅비메디텍). Eight product types covering cell, blood, and tissue samples.
  5. Technology Licensing (HUB Organoids): Inbound technology licensing from HUB (Netherlands) for all organ types combined with outbound sublicensing and technology sharing capabilities.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Next&Bio product offering

Product offering

Core offering

Next&Bio builds and operates an organoid-based precision medicine platform that produces standardized patient-derived organoids (PDOs) and provides drug efficacy evaluation services. Its core offerings include the POINT™ drug sensitivity testing platform, an integrated organoid library with genomic profiles, the Miniature Brain Array for high-throughput CNS drug screening, and MPS (Microphysiological System) organ-on-a-chip technology. The company sells organoids, reagents, and AI image-analysis software to pharmaceutical companies, hospitals, and academic research institutions.

Product overview

Next&Bio is an organoid-based precision medicine platform company offering standardized organoid production and drug evaluation services. The core portfolio consists of the POINT™ drug efficacy evaluation platform, an Organoid Library and Bank System with integrated genomic data, and the Miniature Brain Array™ for HTS-scale brain disease drug screening. The technology suite includes MPS (Microphysiological System) organ-on-a-chip technology and iMag™ nucleic acid extraction kits for quality control. VONet AI software enables 3D organoid structure prediction. The company targets pharmaceutical companies for drug development services and hospitals for clinical precision medicine applications.

Differentiator

Problem solved

Functional benefit

Brands

  • POINT™: 오가노이드 기반 약물 유효성 평가 플랫폼 - Patient-derived Organoid for Individualized Therapeutics
  • Miniature Brain Array™
  • VONet

Products and services

  • POINT™ Drug Efficacy Evaluation Platform Organoid-based drug efficacy evaluation platform that tests anticancer drug sensitivity on patient-derived organoids. Uses standardized 3D culture techniques and high-throughput analysis to select optimal drugs for individual patients. For pharmaceutical companies, hospitals, and oncologists.
  • Organoid Library Patient-derived organoid library integrating genomic profile information. Contains lung, colon, breast, and other cancer organoids with genetic mutation data for research and drug screening applications. The first organoid library in Korea. For researchers and pharmaceutical companies.
  • Organoid Bank System Organoid banking infrastructure with global-standard SOPs for quality assurance, integrated server for data analysis, and security. Near 400 organoid lines from various organs derived from different patients. For hospitals and research institutions.
  • Miniature Brain Array™ High-throughput screening platform using 384 or 768 miniature brains arrayed in 96-well plates. Each plate contains uniform miniature brains suitable for bioimaging analysis and drug screening. For biotech and pharmaceutical companies developing CNS disease drugs.
  • MPS (Microphysiological System) / Organ-on-a-Chip Organ-on-a-chip technology implementing human tissue environment using tissue chips, combining microfluidic chip technology with tissue engineering. Solves organoid inhomogeneity through ultra-precise design. For drug development and cell therapy preclinical evaluation.
  • iMag™ Nucleic Acid Extraction Reagent Kit Magnetic nano bead-based nucleic acid extraction reagent kit for organoid quality verification. 8 product types (tube, bottle, plate formats) for cell, blood, and tissue samples. Class 1 medical device approved by MFDS. Sales rights licensed to Woongbee Meditech.
  • VONet AI Software Deep learning AI software for organoid 3D structure prediction and analysis. Analyzes minimal confocal microscopy images (minimum 11 vs. 60+ traditional) to predict and render 3D organoid architecture, reducing imaging time by 6x.

Quantifiable outcome

  • Organoid imaging analysis time reduced by 6x using VONet AI (from ~60 images to 11 images)
  • +2 more outcomes

Companies that use Next&Bio

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Next&Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Next&Bio partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core, minor and major.

  • Cancer Science Institute of Singapore (CSI) / National University of Singapore (NUS)coreStrategic or Co-development Partner · 30 July 2025Joint organoid research center establishment agreement. Plans to build world's largest Asian patient-derived organoid library from Chinese, Indian, Malay, and other Asian cancer patients in Singapore. Joint preclinical evaluation platform development. Prof. Ashok Venkitaraman (NUS Distinguished Professor) leads research. Next&Bio to deploy organoid research personnel to Singapore.
  • GC Cell (지씨셀)coreStrategic or Co-development Partner · 11 June 2025Joint development of cell therapy preclinical evaluation platform using patient-derived organoids and MPS (Microphysiological System) for CAR-NK cell therapy efficacy testing against intractable solid tumors. Part of Ministry of Health and Welfare national project 'Advanced Biopharmaceutical Nonclinical Efficacy Evaluation Technology Development based on Microphysiological System.'
  • Amplia Therapeutics Limited (호주)coreStrategic or Co-development Partner · 13 November 2024Joint research contract for pancreatic cancer drug development. Next&Bio creates organoids from KRAS-mutated pancreatic cancer patient tissue and evaluates Amplia's drug candidate narmafotinib (AMP945, FAK inhibitor). First collaboration with a global pharmaceutical company leveraging Next&Bio's organoid technology.
  • CytoZen (싸이토젠)minorStrategic or Co-development Partner · 5 April 2024Business agreement for CTC (Circulating Tumor Cell)-based organoid production. CytoZen separates intact live CTCs from blood using proprietary technology; Next&Bio cultures them into organoids for anticancer drug sensitivity testing and metastasis research.
  • Sovargen (소바젠)minorStrategic or Co-development Partner · 28 February 2024Research service contract for brain organoid-based drug efficacy evaluation of Sovargen's intractable brain disease treatments (epilepsy, glioblastoma, Alzheimer's). Next&Bio uses iPSC-derived brain organoids for evaluation.
  • KTR (한국화학융합시험연구원)coreStrategic or Co-development Partner · 13 October 2023Three-way MOU with Kolmar Korea and KTR for advanced alternative test service platform development. Development of OECD TG-compliant alternative testing service platform using 3D in vitro culture technology for cosmetics and pharmaceutical safety assessment.
  • L-Base (엘베이스)minorStrategic or Co-development Partner · 19 September 2023Joint research for new drug development using lung and colorectal cancer patient-derived organoids to evaluate anticancer drug candidate LB217 efficacy. L-Base plans to file IND application with UK MHRA based on results.
  • Chonnam National University Hwasun Hospital (화순전남대학교병원)majorStrategic or Co-development Partner · 23 April 2023MOU for co-establishment of organoid bank. Plans to systematically store organoids from various cancer types and organs for precision medicine and regenerative medicine research. Joint research with cardiologist Prof. Ahn Young-geun on organoid-based regenerative therapy.
  • Korea University Anam Hospital (고려대학교 안암병원)majorStrategic or Co-development Partner · 23 April 2023Joint research agreement for organoid-based precision medicine and personalized drug screening. Collaboration on cancer organoid research, process development for precision medicine, and co-development of personalized cancer treatment.
  • Myongji Hospital (명지병원)majorStrategic or Co-development Partner · 23 April 2023MOU for co-establishment of organoid bank. Focus on liver, stomach, colorectal, and pancreatic cancer organoids for personalized precision medicine services.
  • KIST Europe (한국과학기술연구원 유럽연구소)coreStrategic or Co-development Partner · 11 July 2022Joint research agreement for OECD AOP (Adverse Outcome Pathway) guideline registration using organoid-based animal replacement test methods. Established protocols for liver and lung disease AOP models; registered as OECD development project in June 2022.
  • HUB Organoids (네덜란드)coreTechnology or Integration · 1 January 2021Technology licensing agreement — secured usage rights for all organ types (colon, pancreas, kidney, liver, stomach, lung, ovary) from HUB, the company that pioneered organoid technology under Hans Clevers. Includes technology sharing provisions.
  • Nexel (넥셀)minorGTM or Marketing Partner · 1 January 2021Co-marketing agreement for drug screening services. Collaborative marketing to pharmaceutical companies and research institutions for organoid-based drug screening offerings.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Next&Bio competitors and assessment

Company assessment

Direct peers

  • HUB Organoids: Pioneer of patient-derived organoid technology (founded by Hans Clevers). Next&Bio holds an inbound technology licensing agreement with HUB covering all organ types — they share the same core platform and target pharma R&D customers, making HUB both a licensor and the most direct functional peer.
  • Crown Bioscience: Global preclinical CRO with extensive patient-derived xenograft (PDX) and increasingly organoid-based oncology services. Comparable to Next&Bio in serving pharma drug-efficacy evaluation, but at materially larger scale with global infrastructure.
  • MIMETAS: Dutch organ-on-a-chip / MPS company offering microfluidic 3D tissue models for drug screening. Direct technology overlap with Next&Bio's MPS offering and shared target market of pharma preclinical development.
  • CN Bio: UK-based organ-on-chip / MPS company with single- and multi-organ microphysiological systems used by pharma for ADME/toxicology studies. Comparable to Next&Bio's MPS platform and drug-evaluation service offering.
  • Emulate: US organ-on-chip platform company using microfluidic chips to model human organ physiology for pharma and cosmetics safety testing. Comparable in MPS technology and animal-replacement positioning, including OECD-relevant submissions.
  • InSphero: Swiss 3D cell-culture and organoid company providing in vitro disease models and toxicology services for pharma. Shares Next&Bio's HTS drug-screening business model and target customer base.

Emerging players

  • Curi Bio: Seattle-based company combining iPSC-derived cells, organoids, and MPS platforms for drug discovery and safety assessment. Partial overlap with Next&Bio's brain organoid and MPS offering, though at earlier commercialization stage.
  • DefiniGEN: UK iPSC-derived organoid company providing liver, pancreatic, and intestinal disease models. Comparable in iPSC-derived organoid technology with Next&Bio's standardized organoid production approach.
  • Newcells Biotech: UK-based organoid and iPSC-derived tissue model company with focus on kidney, liver, retina, and lung models for pharma. Adjacent technology overlap with Next&Bio's organoid portfolio.
  • Prellis Biologics: US-based company using 3D-printed lymph node organoids and human tissue models for antibody discovery and therapeutic development. Technology-adjacent to Next&Bio's organoid focus, particularly in producing standardized 3D biological structures.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Next&Bio compliance and trust

Trust signal

Compliance3 records

Next&Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Next&Bio leadership team

Management profile

Number of profiles

Profiles4 records

Next&Bio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Next&Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Next&Bio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Next&Bio

What does Next&Bio do?

Next&Bio builds and operates an organoid-based precision medicine platform that produces standardized patient-derived organoids (PDOs) and provides drug efficacy evaluation services. Its core offerings include the POINT™ drug sensitivity testing platform, an integrated organoid library with genomic profiles, the Miniature Brain Array for high-throughput CNS drug screening, and MPS (Microphysiological System) organ-on-a-chip technology. The company sells organoids, reagents, and AI image-analysis software to pharmaceutical companies, hospitals, and academic research institutions.

Is Next&Bio a public or private company?

Next&Bio is a private company. It is classified as corporate owned and is currently operating.

When was Next&Bio founded?

Next&Bio was founded in 2018. It employs 1 to 10 people.

Where is Next&Bio based?

Next&Bio is headquartered in Seoul, South Korea, in the Asia region.

How does Next&Bio make money?

Five revenue lines are on record. Organoid Library Sales & Distribution is the primary driver. The others are drug Efficacy Evaluation Services (POINT™ Platform), brain Organoid and CNS Disease Modeling Services, iMag™ Nucleic Acid Extraction Kit Sales and technology Licensing (HUB Organoids).

Who are Next&Bio's main competitors?

Direct peers on record are HUB Organoids, Crown Bioscience, MIMETAS, CN Bio, Emulate and InSphero. Emerging players are Curi Bio, DefiniGEN, Newcells Biotech and Prellis Biologics.

Does Next&Bio have an API?

No public API is recorded for Next&Bio.

What industry is Next&Bio in?

Next&Bio's product category is Organoid-based Drug Screening & Precision Medicine. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals